Traders Buy High Volume of Compass Therapeutics Call Options (NASDAQ:CMPX)

Key Points

• Traders purchased 7,069 call options on CMPX—an increase of 411% versus the average—indicating unusually heavy bullish options activity.
• CMPX traded at $5.20 (up $0.10) with 685,334 shares changing hands; the stock has a 52-week range of $1.33–$6.88 and a market cap of about $936 million.
• Institutional investors own 68.43% of the company with several hedge funds materially increasing stakes recently, and analysts carry a consensus “Moderate Buy” with a $13.00 target price.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw unusually large options trading on Tuesday. Traders purchased 7,069 call options on the stock. This is an increase of 411% compared to the average volume of 1,383 call options.

Compass Therapeutics Price Performance

CMPX stock traded up $0.10 during trading on Tuesday, reaching $5.20. The company had a trading volume of 685,334 shares, compared to its average volume of 2,181,968. Compass Therapeutics has a 52 week low of $1.33 and a 52 week high of $6.88. The business has a 50 day moving average of $5.87 and a 200 day moving average of $5.05. The company has a market cap of $935.75 million, a P/E ratio of -12.08 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC raised its holdings in Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company's stock worth $49,354,000 after purchasing an additional 6,951,666 shares in the last quarter. Vivo Capital LLC boosted its holdings in shares of Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. BVF Inc. IL grew its position in shares of Compass Therapeutics by 63.5% in the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company's stock worth $41,697,000 after buying an additional 3,014,842 shares during the period. Balyasny Asset Management L.P. purchased a new stake in shares of Compass Therapeutics in the 3rd quarter worth about $9,892,000. Finally, Braidwell LP bought a new position in shares of Compass Therapeutics in the 4th quarter worth about $14,965,000. 68.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on CMPX shares. Raymond James Financial reaffirmed an "outperform" rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Canaccord Genuity Group set a $13.00 price objective on Compass Therapeutics in a research report on Wednesday, February 4th. Craig Hallum began coverage on Compass Therapeutics in a research note on Friday, February 13th. They set a "buy" rating and a $15.00 target price on the stock. Guggenheim restated a "buy" rating and set a $12.00 target price on shares of Compass Therapeutics in a report on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $13.00.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.